Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 24Not yet recruiting 8Active not recruiting 4Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 26Cisplatin 14Nivolumab 11Cyclophosphamide 11Carboplatin 11Paclitaxel 9Docetaxel 9Radiotherapy, Intensity-Modulated 8Radiotherapy 8Magnetic Resonance Spectroscopy 8Radiosurgery 7Radiation 7Fluorouracil 7Bevacizumab 7Leucovorin 6Irinotecan 6Gemcitabine 6Doxorubicin 6venetoclax 5olaparib 5enzalutamide 5Prednisone 5Pemetrexed 5Oxaliplatin 5Metformin 5Azacitidine 5fludarabine 4atezolizumab 4Taxes 4Surveys and Questionnaires 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Drug Therapy × 30 days × Clear all
NCT03409614 2026-05-18

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Regeneron Pharmaceuticals

Phase 3 Completed
789 enrolled 32 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03570892 2026-05-14

BELINDA

Novartis

Phase 3 Completed
330 enrolled 10 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡